Research
Ubiquinol
33 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction.
Phase 2 randomized, double-blind, placebo-controlled trial of 216 patients with HFpEF testing ubiquinol and/or d-ribose supplementation. The study found significant improvements in KCCQ clinical summary score, vigor score, and EF, and reductions in B-type natriuretic peptides and lactate/adenosine triphosphate ratio. No significant changes in septal E/e' or 6-minute walk test.
Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review.
This multicenter cross-sectional study and systematic literature review analyzed clinical, genetic, and neuroradiological features of 28 patients with KIF1A-related disorders. The study identified novel monoallelic variants and noted that some patients presented secondary impairment of oxidative metabolism. Ubiquinol supplementation was used in 6 patients with subjective benefit.
Ubiquinol supplementation modulates energy metabolism and bone turnover during high intensity exercise.
RCT with 100 healthy and well-trained firemen to assess the effects of ubiquinol supplementation (200 mg/day) on energy metabolism and bone turnover during strenuous exercise. Ubiquinol increased biomarkers of bone formation and improved energy mobilization, suggesting ergogenic benefits for skeletal muscles.
Beneficial Effect of Ubiquinol on Hematological and Inflammatory Signaling during Exercise.
RCT with 100 healthy and well-trained firemen to assess the effects of short-term oral ubiquinol supplementation on inflammatory mediators and hematological parameters during strenuous exercise. Ubiquinol increased RBC, hematocrit, hemoglobin, VEGF, NO, EGF, IL-1ra, and IL-10, while decreasing IL-1, IL-8, and MCP-1, suggesting modulation of inflammatory signaling and a pro-angiogenic effect.
Ubiquinol supplementation in elderly patients undergoing aortic valve replacement: biochemical and clinical aspects.
This RCT evaluated the effects of 400 mg/day ubiquinol supplementation in 50 elderly patients undergoing aortic valve replacement. Ubiquinol counteracted post-operative plasma CoQ10 decline and oxidation, reduced troponin I levels, and prevented adverse outcomes related to left ventricular ejection fraction recovery.
Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study.
Double-blind, placebo-controlled RCT of 228 men with idiopathic infertility, testing 200 mg daily ubiquinol for 26 weeks. Ubiquinol significantly improved sperm density, motility, and morphology compared to placebo. Improvements were sustained but reduced after a 12-week off-drug period.
Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study.
RCT of 20 prediabetic adults evaluating the effect of ubiquinol supplementation (100 mg/day) on plasma oxidized low-density lipoprotein (oxLDL) levels over 12 weeks. The ubiquinol group showed a significant within-group reduction in oxLDL levels compared to baseline, but the between-group difference versus placebo was not significant.
A Randomized, Double-Blind, Two-Treatment, Two-Period, Crossover Study Investigating the Systemic Bioavailability of a Novel Cocrystal Ubiquinol Formulation Compared with a Ubiquinone Formulation in Healthy Adults.
This randomized, double-blind, two-period crossover study compared the oral bioavailability of a novel cocrystal ubiquinol formulation with a ubiquinone formulation in 12 healthy subjects. The ubiquinol formulation demonstrated substantially higher systemic bioavailability than the ubiquinone reference, with no adverse events reported.
Effect of ubiquinol on electrophysiology during high-altitude acclimatization and de-acclimatization: A substudy of the Shigatse CARdiorespiratory fitness (SCARF) randomized clinical trial.
This randomized, double-blind, placebo-controlled trial investigated the effects of ubiquinol on electrophysiology during high-altitude acclimatization and de-acclimatization. Ubiquinol supplementation shortened the hypoxia-induced extended T-Tinterval and reserved maximal heart rate during exercise at high altitude.
Ubiquinol (reduced coenzyme Q10) as a metabolic resuscitator in post-cardiac arrest: A randomized, double-blind, placebo-controlled trial.
This randomized, double-blind, placebo-controlled trial investigated the effects of enteral ubiquinol administration in patients resuscitated from cardiac arrest. Ubiquinol significantly increased plasma coenzyme Q10 levels compared to placebo, but there were no differences in neurological biomarkers or oxygen consumption between the groups.
Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial.
This randomized, double-blind, single-center trial investigated the effects of ubiquinol on endothelial dysfunction in subjects with moderate dyslipidemia. Ubiquinol supplementation significantly increased flow-mediated dilation (FMD) and plasma CoQ10 levels, improved nitric oxide bioavailability, and enhanced LDL antioxidant protection, ameliorating dyslipidemia-related endothelial dysfunction.
Ubiquinol Improves Endothelial Function in Patients with Heart Failure with Reduced Ejection Fraction: A Single-Center, Randomized Double-Blind Placebo-Controlled Crossover Pilot Study.
This randomized, double-blind, placebo-controlled crossover pilot study assessed the effect of ubiquinol 400 mg/day on peripheral endothelial function in 14 patients with heart failure with reduced ejection fraction (HFrEF). Ubiquinol treatment significantly improved endothelial function as measured by the reactive hyperemia index (RHI), suggesting it may be a therapeutic option for HFrEF.
Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial.
Double-blind, placebo-controlled RCT of 50 type 2 diabetes patients examining the effects of 100 mg/d liquid ubiquinol supplementation over 12 weeks. The ubiquinol group showed decreased HbA1c levels, increased antioxidant enzyme activities, and maintained HDL-cholesterol levels compared to placebo.
Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: A randomized placebo-controlled proof-of-pharmacology study.
RCT evaluating simvastatin-induced mitochondrial dysfunction in healthy subjects and the potential reversal by co-enzyme Q10 (ubiquinol). Simvastatin prolonged phosphocreatine recovery time, indicating mitochondrial dysfunction, which was partly reversed by ubiquinol treatment.
Short-term ubiquinol supplementation reduces oxidative stress associated with strenuous exercise in healthy adults: A randomized trial.
RCT of 100 healthy adults examining the effects of short-term Ubiquinol supplementation on oxidative stress associated with strenuous exercise. Ubiquinol reduced oxidative stress markers and increased antioxidant status, suggesting improved endothelial function and muscle recovery.
MicroRNAs as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation.
This randomized controlled trial investigated the effects of ubiquinol supplementation on miRNA profiles and liver enzymes in patients treated with simvastatin. Ubiquinol supplementation was associated with down-regulation of liver enzymes and miRNAs related to apoptotic and inflammatory pathways, suggesting potential hepatoprotective effects.
Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans.
The study examined the relationship between CoQ10 status and serum GGT activity in 416 healthy participants and evaluated the effect of Q10H2 supplementation in 53 healthy males. Q10H2 supplementation significantly decreased serum GGT activity and GGT1 gene expression, suggesting improved oxidative stress.
Ubiquinol decreases monocytic expression and DNA methylation of the pro-inflammatory chemokine ligand 2 gene in humans.
RCT investigating the effects of 150 mg/day ubiquinol supplementation for 14 days on gene expression and DNA methylation in human monocytes. Ubiquinol decreased the expression and DNA methylation of the pro-inflammatory CXCL2 gene, suggesting a gene-specific anti-inflammatory effect.
Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study.
RCT of 62 heart failure patients examining the effects of carni Q-gel (ubiquinol and L-carnitine) supplementation for 12 weeks. The intervention group showed significant reductions in pro-inflammatory cytokines IL-6 and TNF-alpha, increased serum CoQ levels, and improved quality of life and exercise capacity compared to the placebo group.
Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers.
Single-blind, placebo-controlled study evaluating the safety and bioavailability of ubiquinol in healthy subjects after single and 4-week multiple oral administration. Significant absorption was observed with no safety concerns noted for doses up to 300 mg.
The Cocrystal of Ubiquinol: Improved Stability and Bioavailability
The study designed and characterized a new cocrystal of ubiquinol with vitamin B3 nicotinamide, showing improved stability, dissolution properties, and bioavailability compared to the marketed ubiquinol form. The cocrystal exhibited significantly higher maximum ubiquinol concentrations and greater AUC in PK studies.
Effect of gummy candy containing ubiquinol on secretion of saliva: A randomized, double-blind, placebo-controlled parallel-group comparative study and an in vitro study.
A randomized, double-blind, placebo-controlled study examined the effects of ubiquinol on saliva secretion in 40 subjects with slight mouth dryness. Ubiquinol significantly increased saliva flow rate and CoQ10 levels in saliva. Improvements were noted in feelings of tiredness, dryness of the mouth, susceptibility to colds, and diarrhea. An in vitro study showed ubiquinol increased ATP production and reduced oxidative stress in salivary gland cells.
Effect of Ubiquinol Intake on Defecation Frequency and Stool Form: A Prospective, Double-Blinded, Randomized Control Study.
This prospective, double-blind, randomized control study evaluated the effects of ubiquinol intake on defecation frequency and stool form in 41 patients with functional gastrointestinal disorders. Ubiquinol intake for 12 weeks decreased defecation frequency and improved quality of life scores, suggesting potential benefits for bowel habits and quality of life in patients with abdominal distress.
Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes.
This double-blind cross-over RCT studied the effect of ubiquinol supplementation (200 mg/day) on biochemical and oxidative stress indexes in 21 young male athletes after intense exercise. Ubiquinol supplementation prevented exercise-induced CoQ depletion and decreased cytosolic ROS levels, but did not improve physical performance or markers of muscular damage.
Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men.
Double-blind, randomized, crossover trial comparing ubiquinol and ubiquinone supplementation in 10 older men. Ubiquinol significantly increased plasma CoQ10 levels more than ubiquinone, suggesting it is a superior form for enhancing CoQ10 status. Neither form affected oxidative stress biomarkers.
Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial.
RCT of 33 APS patients receiving 200 mg/day ubiquinol or placebo for 1 month. Ubiquinol improved endothelial function, decreased prothrombotic and proinflammatory markers, and modulated gene expression related to thrombosis and inflammation.
Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial.
Randomized, double-blind, placebo-controlled pilot trial assessing the effect of 200 mg enteral ubiquinol on plasma CoQ10 levels in 38 patients with severe sepsis or septic shock. Ubiquinol significantly increased total CoQ10 levels, CoQ10 levels relative to cholesterol, and levels of oxidized and reduced CoQ10 compared to placebo, but no differences were found in secondary outcomes.
Ubiquinol improves symptoms in children with autism.
RCT involving 24 children with autism, aged 3-6 years, receiving ubiquinol supportive therapy at a daily dose of 2 x 50 mg for three months. Ubiquinol improved symptoms such as communication, playing games, sleeping, and food rejection, with CoQ10-TOTAL plasma levels above 2.5 μmol/L.
Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone.
The study compared the bioavailability of ubiquinol versus ubiquinone by measuring plasma CoQ10 levels in 12 healthy volunteers. Ubiquinol showed superior bioavailability, with greater increases in plasma CoQ10 and CoQ10/cholesterol ratio compared to ubiquinone. No side effects were noted.
Impact of oral ubiquinol on blood oxidative stress and exercise performance.
RCT with 15 exercise-trained individuals testing 300mg/day ubiquinol (CoQ10) vs placebo in a cross-over design. CoQ10 increased total and reduced blood CoQ10 levels but did not improve exercise performance or reduce oxidative stress.
Supplemental ubiquinol in patients with advanced congestive heart failure.
Study of seven patients with advanced congestive heart failure showing that switching from ubiquinone to ubiquinol improved plasma CoQ10 levels, ejection fraction, and NYHA class. Ubiquinol demonstrated better absorption and was associated with significant clinical improvement.
Evidence for a Concerted Mechanism of Ubiquinol Oxidation by the Cytochrome bc 1 Complex*
The study examines the mechanism of electron transfer from ubiquinol to the iron-sulfur protein and cytochrome b L within the cytochrome bc 1 complex. It investigates the effects of antimycin on reduction kinetics and the role of low potential redox components in controlling the rate of reduction of cytochrome c 1 and the Rieske iron-sulfur protein.
Combining Ubiquinol With a Statin May Benefit Hypercholesterolaemic Patients With Chronic Heart Failure.
The paper discusses the potential benefits of combining ubiquinol with statin therapy in hypercholesterolaemic patients with chronic heart failure. It highlights the role of coenzyme Q in myocardial bioenergetics and its antioxidant properties, suggesting that ubiquinol may improve myocardial function and reduce skeletal muscle injury when used alongside statins.